Cardiovascular risk reduction - quality prescribing guidance 2026-2029: consultation

19. References

1 Scottish Government, The Scottish Health Survey 2024 - volume 1: main report, 2025

2 British Heart Foundation, Scotland Cardiovascular Disease Factsheet, 2026

3 Scottish Government, Cardiovascular Disease Prevention Scheme – Directed Enhanced Service, NHS Circular: PCA(M)(2025)02, 11 June 2025

4 Scottish Government Polypharmacy Model of Care Group. Polypharmacy guidance, realistic prescribing. 3rd ed. Scottish Government; 2018.

5 Aumônier, S. and Collins, M., Sustainable Healthcare Coalition; Healthcare, Circular Economy Principles and Sustainable Wellbeing, 2020

6 Public Health Scotland, Scottish Cardiac Audit Programme Annual report 2024/25, November 2025

7 Tennison I., Roschnik S., Ashby B. et al., Health care's response to climate change: a carbon footprint assessment of the NHS in England, The Lancet Planetary Health, 5, e84-e92, 2021

8 Rajagopalan, S., McAlister, S., Jay, J. et al. Environmental sustainability in cardiovascular practice: current challenges and future directions. Nature Reviews Cardiology 22, 241–254, 2025

9 Scottish Government, Scotland's Population Health Framework 2025-2035, 2025

10 Conrad N., Molenberghs G., Verbeke G. et al., Trends in cardiovascular disease incidence among 22 million people in the UK over 20 years: population based study. BMJ. 2024 Jun 26;385:e078523., 2024

11 National Records of Scotland, Avoidable Mortality, 2024, March 2026

12 European Society of Cardiology, Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC), European Heart Journal, Volume 42, Issue 34, Pages 3227–3337, 7 September 2021

13 Sattar N., McMurray J.J.V., McInnes I.B., et al., Treating chronic diseases without tackling excess adiposity promotes multimorbidity. Lancet Diabetes Endocrinol. 2023 Jan;11(1):58-62. doi: 10.1016/S2213-8587(22)00317-5. Epub 2022 Nov 29.

14 National cardiovascular disease (CVD) prevention and risk factors toolkit, Right Decision Service, 2025

15 Scottish Intercollegiate Guidelines Network (SIGN), Optimising glycaemic control in people with type 1 diabetes (SIGN 170), 2024

16 British Heart Foundation, Socioeconomic Inequalities In Heart And Circulatory Diseases In Scotland, November 2023

17 Scottish Intercollegiate Guidelines Network (SIGN), Risk estimation and the prevention of cardiovascular disease SIGN 149, 2017

18 European Society of Cardiology, Salt and hypertension: current views, 2022

19 Khan S.U., Lone A.N., Khan M.S., et al. Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis. EClinicalMedicine. 2021 Jul 8;38:100997, 2021

20 Banach M., Lewek J., Surma S., et al., on behalf of the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group and the International Lipid Expert Panel (ILEP), The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis, European Journal of Preventive Cardiology, Volume 30, Issue 18, Pages 1975–1985, December 2023

21 Raggi P., Quyyumi A.A., Henein M.Y., Vaccarino V., Psychosocial stress and cardiovascular disease. American Journal of Preventative Cardiology, 2025 March 19;22:100968.

22 National Institute for Health and Care Excellence (NICE), Guideline NG209, Tobacco: preventing uptake, promoting quitting and treating dependence, November 2021, updated February 2025

23 National Institute for Health and Care Excellence (NICE), Guideline NG136, Hypertension in adults: diagnosis and management, August 2019, Updated February 2026

24 Scottish Government, The Scottish Health Survey 2023 - volume 1: main report, 2024

25 Murray C., Aravkin A., Zheng P. et al., Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019, The Lancet, 396, 1223-1249, 2020

26 The Global Cardiovascular Risk Consortium, Global Effect of Cardiovascular Risk Factors on Lifetime Estimates, New England Journal of Medicine 2025;393:125-138, DOI: 10.1056/NEJMoa2415879, Vol. 393 No. 2, 2025

27 Optimity Matrix, Cost-effectiveness review of blood pressure interventions, A Report to the Blood Pressure System Leadership Board. 2014

28 Niiranen, T., Schnabel, R., Schutte, A., et al., Hypertension and Atrial Fibrillation: A Frontier Review. From the AF-SCREEN International Collaboration. Circulation, 151 (12), 863-877, 2025

29 Ettehad D., Emdin C.A., Kiran A., et al., Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016 Mar 5;387(10022):957-967. Epub 2015 Dec 24. PMID: 26724178.

30 Daugherty S.L., Powers J.D., Magid D.J., et al., Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635–42

31 Howard G., Muntner P., Lackland D.T., et al., Association of Duration of Recognized Hypertension and Stroke Risk: The REGARDS Study, Stroke, Volume 56, Number 1, Pages: 105 – 112, January 2025

32 National Institute for Health and Care Excellence (NICE), Hypertension in adults, Quality standard QS28, March 2013, Updated September 2015

33 Lewis P., George J., Kapil V., et al., Consensus Statement, Adult hypertension referral pathway and therapeutic management: British and Irish Hypertension Society position statement, Journal of Human Hypertension, 2024

34 National Institute for Health and Care Excellence (NICE), Guideline NG133, Hypertension in pregnancy: diagnosis and management, June 2019, Updated April 2023

35 Scotland’s Public Health Observatory, Risk Factors, High cholesterol: key points, March 2025

36 Heart UK website, What is Cholesterol?, accessed July 2026

37 Ference, B.A., Ginsberg H.N., Ian Graham, I., et al., Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel, European Heart Journal, Volume 38, Issue 32, Pages 2459–2472, 21 August 2017

38 National Institute for Health and Care Excellence (NICE), Guideline NG238, Cardiovascular disease: risk assessment and reduction, including lipid modification,, December 2023

39 Heart UK Website, What causes high cholesterol?, last accessed July 2026

40 Chou R., Cantor A., Dana T., et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Journal of the American Medical Association. 2022;328(8):754–771, 2022

41 Cholesterol Treatment Trialists' (CTT) Collaboration, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials, The Lancet, 2010; 376, 1670-1681, 2010

42 Scottish Medicines Consortium website, Medicines advice, bempedoic acid / ezetimibe (Nustendi®), last accessed July 2026

43 British National Formulary, Drugs, Atorvastatin (last accessed July 2026)

44 British National Formulary, Drugs, Rosuvastatin (last accessed July 2026)

45 NHS England, Statin Intolerance Pathway, 2022

46 Scottish Medicines Consortium website, Medicines advice, ezetimibe (Ezetrol), last accessed July 2026

47 NHS England, Summary of National Guidance for Lipid Management for Primary and Secondary Prevention of CVD, Version 7, 2024

48 Battagia A., Alberto D., Font M., et al., Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoint: systematic review and meta-analysis of randomized controlled trials. PLoS One 2015;10:e0124587

49 Laufs U., Ballantyne C.M., Banach M., et al., Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. Journal of Clinical Lipidology, 2022;16(3):286–297.

50 Perera R., McFadden E., McLellan J., et al., Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling. Health Technology Assessment 2015;19(100).

51 Homer K., Robson J., Solaiman S., Reducing liver function tests for statin monitoring: an observational comparison of two clinical commissioning groups. British Journal of General Practice, 2017 Mar;67(656):e194-e200. doi: 10.3399/bjgp17X689365. Epub 2017

52 Averbukh L.D., Turshudzhyan A., Wu D.C., Wu G.Y., Statin-induced Liver Injury Patterns: A Clinical Review. Journal of Clinical and Translational Hepatology, 2022 Jun 28;10(3):543-552. doi: 10.14218/JCTH.2021.00271. Epub 2022

53 Thapar M., Russo M.W., Bonkovsky H.L., Statins and liver injury. . Gastroenterology & Hepatology, 2013 Sep;9(9):605-606. PMID: 24729773; PMCID: PMC3983981.

54 Targher G., Byrne C.D., Tilg H., MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024 Mar 7;73(4):691-702

55 Electronic medicines compendium, Bempedoic acid Nilemdo 180mg film-coated tablets - Summary of Product Characteristics, 11743 section 4.8, last updated May 2026

56 Electronic medicines compendium, Ezetimibe 10 mg tablets - Summary of Product Characteristics, 9278 section 4.8, last updated June 2026

57 Vinogradova Y., Coupland C., Brindle P., Hippisley-Cox J., Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database, BMJ 2016; 353:i3305, June 2016

58 Thalmann, I., Preiss, D. Schlackow, I., et al., Determinants of statin initiation and discontinuation in the secondary prevention of atherosclerotic cardiovascular disease in Scotland during 2009–2017, European Heart Journal, Volume 41, Issue Supplement_2, November 2020

59 Matthews A., Herrett E., Gasparrini A., et al., Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data, BMJ 2016; 353:i3283, June 2016

60 Reith C., Baigent C., Blackwell L. et al., Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials, The Lancet; 400, 832-845, 2022

61 Herrett E., Williamson E., Brack K., et al., Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials, BMJ, 2021;372:n135

62 Reith C., Preiss D., Blackwell L. et al., Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. The Lancet Diabetes & Endocrinology, 2024; 12, 306-319

63 Sattar N. Statins and diabetes: What are the connections? Best Practice and Research Clinical Endocrinology and Metabolism, 2023 May;37(3):101749. doi: 10.1016/j.beem.2023.101749. Epub 2023

64 National Institute for Health and Care Excellence (NICE), Clinical Knowledge Summary, Hypercholesterolaemia-familial, prescribing information: bempedoic-acid, last revised May 2025

65 National Institute for Health and Care Excellence (NICE), Guideline CG71, Familial hypercholesterolaemia: identification and management, August 2008, Updated October 2019

66 Scottish Medicines Consortium website, Medicines Advice, Alirocumab (Praluent), August 2016

67 Scottish Medicines Consortium website, Medicines Advice, Evolocumab (Repatha), February 2017

68 Scottish Medicines Consortium website, Medicines Advice, Inclisiran (Leqvio), August 2021

69 World Health Organisation, Factsheet: Obesity and overweight, December 2025

70 NHS inform website, Obesity, last updated September 2025

71 UK Health Security Agency, Designing a ‘whole systems approach’ to prevent and tackle obesity, October 2015

72 Rubino F., Cummings D.E., Eckel R.H., et al., Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025 Mar;13(3):221-262. doi: 10.1016/S2213-8587(24)00316-4. Epub 2025 Jan 14. Erratum in: Lancet Diabetes Endocrinol. 2025 Mar;13(3):e6.

73 Kivimäki M., Strandberg T., Pentti J., et al., Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study. Lancet Diabetes Endocrinol. 2022 Apr;10(4):253-263. doi: 10.1016/S2213-8587(22)00033-X. Epub 2022

74 Volpe M., Gallo G., Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC). Frontiers in Cardiovascular Medicine, 2023 Mar 13;10:1136340.

75 National Institute for Health and Care Excellence (NICE), Guideline NG246, Overweight and obesity management, January 2025, Updated January 2026

76 British Heart Foundation website, Why your waist size matters, October 2024

77 Vallis M., Piccinini-Vallis H., Sharma A.M., Freedhoff Y., Clinical review: modified 5 As: minimal intervention for obesity counseling in primary care. Canadian Family Physician Medecin de Famille Canadien. 2013 Jan;59(1):27-31.

78 Medicines and Healthcare products Regulatory Agency (MHRA) Press release: MHRA approves GLP –1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults, 23 July 2024

79 Lincoff A.M., Brown-Frandsen K., Colhoun H.M., et al., Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine 2023;389(24):2221-32. 48

80 Rosenstock J., Wysham C., Frias J.P., et al., Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 2021;398(10295):143-55

81 Scottish Intercollegiate Guideline Network (SIGN), SIGN172 Prevention and remission of type 2 diabetes, March 2025

82 Scottish Medicines Consortium website, Medicines advice: Semaglutide (Wegovy), June 2026

83 NICE, British National Formulary (BNF) website, Drugs: Tirzepatide, last accessed July 2026

84 Lincoff, A.M., Brown-Frandsen, K., Colhoun, H.M., et al., Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, The New England Journal of Medicine, 2023;389:2221-2232

85 Packer, M., Zile, M.R. Kramer, C.M., et al., Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity, The New England Journal of Medicine, 2025;392:427-437

86 Scottish Medicines Consortium Advice on new medicines (SMC2497), Semaglutide, 0.25mg, 0.5mg, 1mg, 1.7mg, and 2.4mg FlexTouch solution for injection in pre-filled pen (Wegovy®), December 2022, issued September 2023

87 Scottish Medicines Consortium Advice on new medicines (SMC2633) Tirzepatide (Mounjaro®), April 2024

88 Medicines & Healthcare products Regulatory Agency (MHRA), Guidance: GLP-1 medicines for weight loss and diabetes: what you need to know, Updated February 2026

89 Electronic medicines compendium, Mounjaro KwikPen 5mg solution for injection in pre-filled pen - Summary of Product Characteristics, last updated April 2026

90 Electronic medicines compendium, Wegovy 0.25 mg, FlexTouch solution for injection in pre-filled pen - Summary of Product Characteristics, last updated July 2026

91 Scottish Government and NHS Scotland, Consensus statement: national criteria for the prioritisation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and GLP-1 RA/glucose-dependent insulinotropic polypeptide receptor agonists (GIP RAs) for the treatment of obesity in NHS Scotland, September 2024

92 Ayoub M., Chela H., Amin N., et al., Pancreatitis Risk Associated with GLP-1 Receptor Agonists, Considered as a Single Class, in a Comorbidity-Free Subgroup of Type 2 Diabetes Patients in the United States: A Propensity Score-Matched Analysis. Journal of Clinical Medicine. 2025; 14(3):944.

93 NICE, British National Formulary (BNF) website, Drugs: Semaglutide, last accessed July 2026

94 Electronic medicines compendium, Mounjaro KwikPen 10mg solution for injection in pre-filled pen - Summary of Product Characteristics, last updated April 2026

95 British Menopause Society (BMS), BMS Tool for Clinicians, Progestogens and endometrial protection, 2026

96 NHS Scotland, Scottish Diabetes Group, Scottish Diabetes Survey 2023, 2024

97 Tun N.N., Arunagirinathan G., Munshi S.K., Pappachan J.M., Diabetes mellitus and stroke: A clinical update. World Journal of Diabetes. 2017 Jun 15;8(6):235-248.

98 Dal Canto E., Ceriello A., Rydén L., et al., Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. European Journal of Preventative Cardiology, 2019 Dec;26(2_suppl):25-32

99 Stratton I.M., Adler A.I., Neil H.A.W., et al., Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 2000; 321 :405

100 Lang A., Maalmi H., Rathmann W., et al., Prediabetes and risk of mortality, diabetes-related complications and comorbidities: umbrella review of meta-analyses of prospective studies. Diabetologia. 2022 Feb;65(2):275-285

101 Scottish Government, Type 2 Diabetes Mellitus - quality prescribing strategy: improvement guide 2024 to 2027, 2024

102 Scottish Intercollegiate Guideline Network, SIGN 154 Pharmacological management of glycaemic control in people with type 2 diabetes, 2017, Revised April 2024

103 Holman, R.R., Paul, S.K., Bethel, M.A., et al., 2008. 10-year follow-up of intensive glucose control in type 2 diabetes. New England Journal of Medicine, 359(15), pp.1577-1589.

104 Maruthur, N.M., Tseng, E., Hutfless, s., et al. Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. Annals of Internal Medicine, 2016;164:740-751. Epub 19 April 2016

105 Scotland’s Public Health Observatory, Tobacco use: smoking attributable deaths, last updated June 2026

106 Hackshaw A., Morris J.K., Boniface S., et al. Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. BMJ. 2018 Jan 24;360:j5855.

107 Prochaska, J.O. and DiClemente, C.C., 1983. Stages and processes of self-change of smoking: toward an integrative model of change. Journal of Consulting and Clinical Psychology, 51(3), p.390.

108 Office for National Statistics, Adult smoking habits in the UK: 2024, November 2025

109 Agrawal S., Evison M., Ananth S., et al. Medical management of inpatients with tobacco dependency. Thorax 2024;79(suppl 1):3–11

110 NICE Clinical Knowledge Summary, Smoking cessation, Prescribing information, Varenicline, last updated January 2026

111 NHS inform, Stop smoking medication, last updated July 2026

112 Smoking in Scotland website, E Cigarettes Latest Trends, last updated April 2026

113 Hartmann-Boyce J., McRobbie H., Butler A.R., et al., Electronic cigarettes for smoking cessation. Cochrane Database of Systematic Reviews 2021, Issue 9. Art. No.: CD010216.

114 Inchley, J., Mabelis, J., Brown, J., et al. Health Behaviour in School-aged Children (HBSC) 2022 Survey in Scotland: National Report. MRC/CSO Social and Public Health Sciences Unit, University of Glasgow, 2023

115 McNeill, A., Simonavičius, E., Brose, L.S., et al. Nicotine vaping in England: an evidence update including health risks and perceptions. A report commissioned by the Office for Health Improvement and Disparities. London: Office for Health Improvement and Disparities, 2022

116 World Health Organization WHO report on the global tobacco epidemic 2021: addressing new and emerging products, July 2021

117 Scottish Government, Action on single-use vapes, February 2023, Update March 2025

118 Shi Y., Warner D.O., Surgery as a teachable moment for smoking cessation. Anesthesiology. 2010 Jan;112(1):102-7.

119 Turan A., Mascha E.J., Roberman D., et al., Smoking and perioperative outcomes. Anesthesiology. 2011 Apr;114(4):837-46

120 Laupacis A., Sackett D., Roberts R., An Assessment of Clinically Useful Measures of the Consequences of Treatment. New England Journal of Medicine. 1988;318(26):1728-1733

121 Cook R., Sackett D., The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310(6977):452-454

122 McAlister, F.A., The “number needed to treat” turns 20—and continues to be used and misused. Cmaj, 2008; 179(6), pp.549-553

123 Guthrie B., Thompson A., Dumbreck S., et al., Better guidelines for better care: accounting for multimorbidity in clinical guidelines – structured examination of exemplar guidelines and health economic modelling. Health Services Delivery Research 2017